Marshall Wace
VTYX

Marshall Wace’s Ventyx Biosciences VTYX Stock Holding History

Marshall Wace’s Portfolio VTYX Stock Details VTYX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-2,316,275
Closed -$7.2M – 3527
2025
Q3 		$7.2M Sell
2,316,275
-80,548
-3% -$213K 0.01% 1045
2025
Q2 		$5.13M Buy
+2,396,823
New +$3.87M 0.01% 1128
2024
Q4 		– Sell
-178,514
Closed -$389K – 3044
2024
Q3 		$389K Buy
+178,514
New +$410K ﹤0.01% 2017
2024
Q1 		– Sell
-522,859
Closed -$1.29M – 2841
2023
Q4 		$1.29M Buy
522,859
+188,121
+56% +$1.79M ﹤0.01% 1392
2023
Q3 		$11.6M Buy
334,738
+94,738
+39% +$3.28M 0.02% 603
2023
Q2 		$7.87M Sell
240,000
-198,658
-45% -$6.85M 0.02% 840
2023
Q1 		$14.7M Buy
+438,658
New +$17.1M 0.03% 578

Other funds holding VTYX

AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Marshall Wace's VTYX Position: Q4 2025 in Review

Marshall Wace sold out of Ventyx Biosciences (VTYX) in Q4 2025, closing a stake of 2,316,275 shares — an estimated $7.2M sold.

Marshall Wace first reported a position in VTYX in Q1 2023 and held it in 7 quarters. The position peaked at $14.7M in Q1 2023. 139 funds tracked by Wall St. Rank hold VTYX as of Q4 2025.

  • Marshall Wace reported no remaining Ventyx Biosciences position as of Q4 2025 after selling out during the quarter.
  • Marshall Wace sold 2,316,275 Ventyx Biosciences shares in Q4 2025, an estimated $7.2M.
  • Marshall Wace first reported a position in Ventyx Biosciences in Q1 2023 and held it in 7 quarters.
  • Marshall Wace's Ventyx Biosciences position peaked at $14.7M in Q1 2023.
  • 139 funds tracked by Wall St. Rank held Ventyx Biosciences as of Q4 2025.

Based on Marshall Wace's 13F filing for Q4 2025, filed 13 Feb 2026.